Terms: = Lung cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
17057 results:
1. The association of egfr amplification with aberrant exon 20 insertion report using the cobas egfr Mutation Test v2.
Zhang MS; Yeh YC; Huang HN; Lin LW; Huang YL; Wang LC; Yao LJ; Hung TC; Tseng YF; Lee YH; Liao WY; Shih JY; Hsieh MS
PLoS One; 2024; 19(4):e0301120. PubMed ID: 38687753
[TBL] [Abstract] [Full Text] [Related]
2. Decoding dynamic interactions between egfr-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract] [Full Text] [Related]
3. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract] [Full Text] [Related]
4. Design and Evaluation of a Humanized Anti-egfr huscFv Antibody Fragment in Combination With Metformin in A549 Cells
Solis-Estrada J; Arredondo-Espinoza E; Pioquinto-Ávila E; González-Cruz AO; Zarate X; Balderas-Rentería I
Anticancer Res; 2024 May; 44(5):1955-1962. PubMed ID: 38677771
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
Bilgin B; Kuralay Y; Yucel S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):215. PubMed ID: 38668879
[TBL] [Abstract] [Full Text] [Related]
6. Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer.
Wang Y; Huang Z; Li B; Xue J; Guo C; Bing Z; Zheng Z; Song Y; Xu Y; Huang G; Li H; Yu X; Xia Y; Li R; Si X; Zhang L; Li J; Song L; Xiong Y; Gu D; Song M; Zhou Z; Chen R; Feng Z; Bie Z; Li X; Yang H; Li S; Liang N
Cancer Immunol Immunother; 2024 Apr; 73(6):111. PubMed ID: 38668781
[TBL] [Abstract] [Full Text] [Related]
7. Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell lung cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence.
Moulson R; Law J; Sacher A; Liu G; Shepherd FA; Bradbury P; Eng L; Iczkovitz S; Abbie E; Elia-Pacitti J; Ewara EM; Mokriak V; Weiss J; Pettengell C; Leighl NB
Curr Oncol; 2024 Apr; 31(4):1947-1960. PubMed ID: 38668049
[TBL] [Abstract] [Full Text] [Related]
8. Gold Nanoprobes for Detection of a Crucial egfr Deletion for Early Diagnosis of Non-Small-Cell lung cancer.
Enea M; Nuekaew A; Franco R; Pereira E
Biosensors (Basel); 2024 Mar; 14(4):. PubMed ID: 38667155
[TBL] [Abstract] [Full Text] [Related]
9. Gefitinib Induces Apoptosis in NSCLC Cells by Promoting Glutaminolysis and Inhibiting the MEK/ERK Signaling Pathway.
Zhang Y; Liu H; Liu X; Lang L
Discov Med; 2024 Apr; 36(183):836-841. PubMed ID: 38665031
[TBL] [Abstract] [Full Text] [Related]
10. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
12. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell lung cancer Treated with PD-1/PD-L1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
13. egfr Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell lung cancer.
Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M
Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic implications of combining egfr-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.
Liang S; Wang H; Zhang Y; Tian H; Li C; Hua D
Cancer Med; 2024 Apr; 13(8):e7208. PubMed ID: 38659399
[TBL] [Abstract] [Full Text] [Related]
15. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
16. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in egfr mutant lung cancer.
Pfeifer M; Brammeld JS; Price S; Pilling J; Bhavsar D; Farcas A; Bateson J; Sundarrajan A; Miragaia RJ; Guan N; Arnold S; Tariq L; Grondine M; Talbot S; Guerriero ML; O'Neill DJ; Young J; Company C; Dunn S; Thorpe H; Martin MJ; Maratea K; Barrell D; Ahdesmaki M; Mettetal JT; ; Brownell J; McDermott U
Commun Biol; 2024 Apr; 7(1):497. PubMed ID: 38658677
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation.
Gao E; Wang Y; Fan GL; Xu G; Wu ZY; Liu ZJ; Liu JC; Mao LF; Hou X; Li S
Sci Rep; 2024 Apr; 14(1):9223. PubMed ID: 38649732
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract] [Full Text] [Related]
19. Neoadjuvant egfr-TKI therapy in Non-Small cell lung cancer.
Grant C; Nagasaka M
Cancer Treat Rev; 2024 May; 126():102724. PubMed ID: 38636443
[TBL] [Abstract] [Full Text] [Related]
20. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
[Next]
